You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業(09939.HK)及中國抗體(03681.HK)續挫13%及7.4% 康希諾反覆彈3%
阿思達克 05-27 15:44
仍未有盈利掛牌第四天的開拓藥業-B(09939.HK)繼首掛日反覆高見22.95元行人止步,收市僅較上市價20.15元高6.7%後,股價連跌第三天,今天跌破首掛日所造低位20.1元,最低見16.24元,現造17.54元,急挫13%,成交已較昨天全日急增3倍至2,024萬股,涉資3.72億元。

其餘未有盈利「B仔股」個別發展。中國抗體製藥-B(03681.HK)續跌7.4%報3.9元,遠低去年11月上市價7.6元。該公司大股東擬以每股3.5元出售4,133萬股予執董兼總裁強靜擁有格擎生物。

諾誠健華-B(09969.HK)連跌第二天,今早高開見15.16元受制10天線,掉頭失守20天線(14.76元),最低見14.16元,現造14.26元,續跌4.3%;康寧傑瑞製藥-B(09966.HK)反覆吐2.6%報18.92元。

不過,華領醫藥-B(02552.HK)連彈第二天曾重越10天線(4.58元),高見4.61元,現造4.54元,續彈6%。康希諾生物-B(06185.HK)扭兩連挫,今天反覆(高低見179元/152元)回升3%報174.9元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account